|
|
|
|
| LEADER |
01830nam a2200301 u 4500 |
| 001 |
EB001839911 |
| 003 |
EBX01000000000000001003900 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 245 |
0 |
0 |
|a Daptomycin for methicillin-resistant and methicillin-sensitive staphylococcus aureus infection
|h Elektronische Ressource
|b a review of clinical effectiveness, cost-effectiveness and guidelines
|c prepared by Canadian Agency for Drus and Technologies in Health
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH Rapid Response Service
|c 2016, 2016
|
| 300 |
|
|
|a 1 PDF file (40 pages)
|b illustration
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Staphylococcus aureus / drug effects
|
| 653 |
|
|
|a Staphylococcal Infections / drug therapy
|
| 653 |
|
|
|a Bacteremia / drug therapy
|
| 653 |
|
|
|a Methicillin Resistance / drug effects
|
| 653 |
|
|
|a Daptomycin / therapeutic use
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Rapid response report: summary with critical appraisal
|
| 500 |
|
|
|a "21 January 2016."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK343998
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The aim of this review is to summarize evidence on the comparative clinical and cost effectiveness of daptomycin to other antibiotics for the treatment of bacteremia and other infections caused by methicillin susceptible staphylococcus aureus (MSSA) or methicillin resistant staphylococcus aureus (MRSA), and to summarize evidence-based guidelines regarding the use of daptomycin for MRSA and MSSA bacteremia or infection
|